Compare HII & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HII | HUMAW |
|---|---|---|
| Founded | 1886 | 2004 |
| Country | United States | United States |
| Employees | N/A | 220 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | N/A |
| IPO Year | N/A | N/A |
| Metric | HII | HUMAW |
|---|---|---|
| Price | $426.25 | $0.15 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $342.17 | N/A |
| AVG Volume (30 Days) | ★ 610.9K | 14.2K |
| Earning Date | 02-05-2026 | 03-21-2025 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 14.50 | N/A |
| Revenue | ★ $12,012,000,000.00 | N/A |
| Revenue This Year | $5.79 | N/A |
| Revenue Next Year | $5.42 | N/A |
| P/E Ratio | $28.89 | ★ N/A |
| Revenue Growth | ★ 2.60 | N/A |
| 52 Week Low | $158.88 | $1.18 |
| 52 Week High | $425.12 | $1.34 |
| Indicator | HII | HUMAW |
|---|---|---|
| Relative Strength Index (RSI) | 81.61 | 55.89 |
| Support Level | $401.20 | $0.10 |
| Resistance Level | $425.12 | $0.15 |
| Average True Range (ATR) | 11.24 | 0.03 |
| MACD | 6.06 | 0.01 |
| Stochastic Oscillator | 98.60 | 96.15 |
Huntington Ingalls Industries is the largest independent military shipbuilder in the US, spun out from Northrop Grumman in 2011. It operates three segments, two of which are storied shipyards: Ingalls produces non-nuclear-powered ships including amphibious landing ships and Arleigh Burke-class destroyers, while Newport News produces nuclear-powered ships as the only producer of Gerald Ford-class aircraft carriers and a major subcontractor on Virginia- and Columbia-class nuclear submarines. HII shares production of destroyers and nuclear submarines with General Dynamics' Bath Iron Works and Electric Boat shipyards, respectively. The company's mission technologies segment produces uncrewed sea vessels and provides a range of IT and other services to US government agencies.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.